|
|
| | 2-Bromo-2-deoxy-5-methyluridine-3,5-diacetate Basic information |
| Product Name: | 2-Bromo-2-deoxy-5-methyluridine-3,5-diacetate | | Synonyms: | 2-Bromo-2-deoxy-5-methyluridine-3,5-diacetate;2'-Bromothymidine;2'-BroMo-2'-deoxy-5-Methyluridine;Uridine, 2'-bromo-2'-deoxy-5-methyl-;2’-Bromo-2’-deoxy-5-methyluridine;2′-bromo-2′-deoxythymidine, CAS 95585-76-5 | | CAS: | 95585-76-5 | | MF: | C10H13BrN2O5 | | MW: | 321.12 | | EINECS: | | | Product Categories: | | | Mol File: | 95585-76-5.mol |  |
| | 2-Bromo-2-deoxy-5-methyluridine-3,5-diacetate Chemical Properties |
| density | 1.772±0.06 g/cm3(Predicted) | | pka | 9.55±0.10(Predicted) |
| | 2-Bromo-2-deoxy-5-methyluridine-3,5-diacetate Usage And Synthesis |
| Uses | 2’-Bromo-2’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 2-Bromo-2-deoxy-5-methyluridine-3,5-diacetate Preparation Products And Raw materials |
|